These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31813614)

  • 1. Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy.
    Servais L; Straathof CSM; Schara U; Klein A; Leinonen M; Hasham S; Meier T; De Waele L; Gordish-Dressman H; McDonald CM; Mayer OH; Voit T; Mercuri E; Buyse GM;
    Neuromuscul Disord; 2020 Jan; 30(1):5-16. PubMed ID: 31813614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
    Buyse GM; Goemans N; van den Hauwe M; Meier T
    Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
    Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
    Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy.
    Buyse GM; Voit T; Schara U; Straathof CS; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; Rummey C; Leinonen M; Mayer OH; Spagnolo P; Meier T; McDonald CM;
    Pediatr Pulmonol; 2017 Apr; 52(4):508-515. PubMed ID: 27571420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy.
    Mayer OH; Leinonen M; Rummey C; Meier T; Buyse GM;
    J Neuromuscul Dis; 2017; 4(3):189-198. PubMed ID: 28869486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph.
    Buyse GM; Rummey C; Meier T; Leinonen M; Voit T; McDonald CM; Mayer OH
    J Neuromuscul Dis; 2018; 5(4):419-430. PubMed ID: 30282375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy.
    McDonald CM; Meier T; Voit T; Schara U; Straathof CS; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; Rummey C; Leinonen M; Spagnolo P; Buyse GM;
    Neuromuscul Disord; 2016 Aug; 26(8):473-80. PubMed ID: 27238057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
    Buyse GM; Goemans N; van den Hauwe M; Thijs D; de Groot IJ; Schara U; Ceulemans B; Meier T; Mertens L
    Neuromuscul Disord; 2011 Jun; 21(6):396-405. PubMed ID: 21435876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
    Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
    Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy.
    McKim DA; Katz SL; Barrowman N; Ni A; LeBlanc C
    Arch Phys Med Rehabil; 2012 Jul; 93(7):1117-22. PubMed ID: 22421625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy.
    Meier T; Rummey C; Leinonen M; Spagnolo P; Mayer OH; Buyse GM;
    Neuromuscul Disord; 2017 Apr; 27(4):307-314. PubMed ID: 28189481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
    Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E
    Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of pulmonary function in Duchenne Muscular Dystrophy.
    Mayer OH; Finkel RS; Rummey C; Benton MJ; Glanzman AM; Flickinger J; Lindström BM; Meier T
    Pediatr Pulmonol; 2015 May; 50(5):487-94. PubMed ID: 25755201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of idebenone in Duchenne muscular dystrophy.
    Mercuri E; Muntoni F
    Lancet; 2015 May; 385(9979):1704-1706. PubMed ID: 25907159
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naïve Patients with Duchenne Muscular Dystrophy.
    Sawnani H; Horn PS; Wong B; Darmahkasih A; Rybalsky I; Shellenbarger KC; Tian C; Rutter MM; Simakajornboon N; Amin R; Gurbani N; Pascoe J; Burrows C; Khirani S; Amaddeo A; Fauroux B
    J Pediatr; 2019 Jul; 210():194-200.e2. PubMed ID: 30955791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
    Khan N; Eliopoulos H; Han L; Kinane TB; Lowes LP; Mendell JR; Gordish-Dressman H; Henricson EK; McDonald CM;
    J Neuromuscul Dis; 2019; 6(2):213-225. PubMed ID: 30856119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of body habitus and respiratory function in Duchenne muscular dystrophy.
    Chew K; Carey K; Ho G; Mallitt KA; Widger J; Farrar M
    Respir Med; 2016 Oct; 119():35-40. PubMed ID: 27692145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids.
    McDonald CM; Gordish-Dressman H; Henricson EK; Duong T; Joyce NC; Jhawar S; Leinonen M; Hsu F; Connolly AM; Cnaan A; Abresch RT;
    Neuromuscul Disord; 2018 Nov; 28(11):897-909. PubMed ID: 30336970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.